Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

517 related articles for article (PubMed ID: 32342603)

  • 1. Combination of CD47 and signal-regulatory protein-α constituting the "don't eat me signal" is a prognostic factor in diffuse large B-cell lymphoma.
    Kazama R; Miyoshi H; Takeuchi M; Miyawaki K; Nakashima K; Yoshida N; Kawamoto K; Yanagida E; Yamada K; Umeno T; Suzuki T; Kato K; Takizawa J; Seto M; Akashi K; Ohshima K
    Cancer Sci; 2020 Jul; 111(7):2608-2619. PubMed ID: 32342603
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinicopathological analysis of immunohistochemical expression of CD47 and SIRPα in adult T-cell leukemia/lymphoma.
    Yanagida E; Miyoshi H; Takeuchi M; Yoshida N; Nakashima K; Yamada K; Umeno T; Shimasaki Y; Furuta T; Seto M; Ohshima K
    Hematol Oncol; 2020 Dec; 38(5):680-688. PubMed ID: 32569413
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD47 Expression Defines Efficacy of Rituximab with CHOP in Non-Germinal Center B-cell (Non-GCB) Diffuse Large B-cell Lymphoma Patients (DLBCL), but Not in GCB DLBCL.
    Bouwstra R; He Y; de Boer J; Kooistra H; Cendrowicz E; Fehrmann RSN; Ammatuna E; Zu Eulenburg C; Nijland M; Huls G; Bremer E; van Meerten T
    Cancer Immunol Res; 2019 Oct; 7(10):1663-1671. PubMed ID: 31409608
    [TBL] [Abstract][Full Text] [Related]  

  • 4. "Velcro" engineering of high affinity CD47 ectodomain as signal regulatory protein α (SIRPα) antagonists that enhance antibody-dependent cellular phagocytosis.
    Ho CC; Guo N; Sockolosky JT; Ring AM; Weiskopf K; Özkan E; Mori Y; Weissman IL; Garcia KC
    J Biol Chem; 2015 May; 290(20):12650-63. PubMed ID: 25837251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group.
    Staiger AM; Ziepert M; Horn H; Scott DW; Barth TFE; Bernd HW; Feller AC; Klapper W; Szczepanowski M; Hummel M; Stein H; Lenze D; Hansmann ML; Hartmann S; Möller P; Cogliatti S; Lenz G; Trümper L; Löffler M; Schmitz N; Pfreundschuh M; Rosenwald A; Ott G;
    J Clin Oncol; 2017 Aug; 35(22):2515-2526. PubMed ID: 28525305
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DSP107 combines inhibition of CD47/SIRPα axis with activation of 4-1BB to trigger anticancer immunity.
    Cendrowicz E; Jacob L; Greenwald S; Tamir A; Pecker I; Tabakman R; Ghantous L; Tamir L; Kahn R; Avichzer J; Aronin A; Amsili S; Zorde-Khvalevsky E; Gozlan Y; Vlaming M; Huls G; van Meerten T; Dranitzki ME; Foley-Comer A; Pereg Y; Peled A; Chajut A; Bremer E
    J Exp Clin Cancer Res; 2022 Mar; 41(1):97. PubMed ID: 35287686
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blocking "don't eat me" signal of CD47-SIRPα in hematological malignancies, an in-depth review.
    Russ A; Hua AB; Montfort WR; Rahman B; Riaz IB; Khalid MU; Carew JS; Nawrocki ST; Persky D; Anwer F
    Blood Rev; 2018 Nov; 32(6):480-489. PubMed ID: 29709247
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The regulation of CD47-SIRPα signaling axis by microRNAs in combination with conventional cytotoxic drugs together with the help of nano-delivery: a choice for therapy?
    Beizavi Z; Gheibihayat SM; Moghadasian H; Zare H; Yeganeh BS; Askari H; Vakili S; Tajbakhsh A; Savardashtaki A
    Mol Biol Rep; 2021 Jul; 48(7):5707-5722. PubMed ID: 34275112
    [TBL] [Abstract][Full Text] [Related]  

  • 9. COO and MYC/BCL2 status do not predict outcome among patients with stage I/II DLBCL: a retrospective multicenter study.
    Barraclough A; Alzahrani M; Ettrup MS; Bishton M; van Vliet C; Farinha P; Gould C; Birch S; Sehn LH; Sovani V; Ward MS; Augustson B; Biccler J; Connors JM; Scott DW; Gandhi MK; Savage KJ; El-Galaly T; Villa D; Cheah CY
    Blood Adv; 2019 Jul; 3(13):2013-2021. PubMed ID: 31285189
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exosome-SIRPα, a CD47 blockade increases cancer cell phagocytosis.
    Koh E; Lee EJ; Nam GH; Hong Y; Cho E; Yang Y; Kim IS
    Biomaterials; 2017 Mar; 121():121-129. PubMed ID: 28086180
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting the CD47-SIRPα signaling axis: current studies on B-cell lymphoma immunotherapy.
    Zhang J; Jin S; Guo X; Qian W
    J Int Med Res; 2018 Nov; 46(11):4418-4426. PubMed ID: 30226089
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Young patients with non-germinal center B-cell-like diffuse large B-cell lymphoma benefit from intensified chemotherapy with ACVBP plus rituximab compared with CHOP plus rituximab: analysis of data from the Groupe d'Etudes des Lymphomes de l'Adulte/lymphoma study association phase III trial LNH 03-2B.
    Molina TJ; Canioni D; Copie-Bergman C; Recher C; Brière J; Haioun C; Berger F; Fermé C; Copin MC; Casasnovas O; Thieblemont C; Petrella T; Leroy K; Salles G; Fabiani B; Morschauser F; Mounier N; Coiffier B; Jardin F; Gaulard P; Jais JP; Tilly H
    J Clin Oncol; 2014 Dec; 32(35):3996-4003. PubMed ID: 25385729
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.
    Green TM; Young KH; Visco C; Xu-Monette ZY; Orazi A; Go RS; Nielsen O; Gadeberg OV; Mourits-Andersen T; Frederiksen M; Pedersen LM; Møller MB
    J Clin Oncol; 2012 Oct; 30(28):3460-7. PubMed ID: 22665537
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinicopathological analysis of CD47 and signal regulatory protein alpha expression in myeloid sarcoma patients: CD47 expression is a favourable prognostic factor.
    Tanaka K; Miyoshi H; Kawamoto K; Shimasaki Y; Nakashima K; Imamoto T; Yamada K; Takeuchi M; Moritsubo M; Furuta T; Kohno K; Tamura S; Sonoki T; Ohshima K
    Pathology; 2024 Feb; 56(1):81-91. PubMed ID: 38110323
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low HIP1R mRNA and protein expression are associated with worse survival in diffuse large B-cell lymphoma patients treated with R-CHOP.
    Wong KK; Ch'ng ES; Loo SK; Husin A; Muruzabal MA; Møller MB; Pedersen LM; Pomposo MP; Gaafar A; Banham AH; Green TM; Lawrie CH
    Exp Mol Pathol; 2015 Dec; 99(3):537-45. PubMed ID: 26341140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic effect of Ki-67 expression in rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone-treated diffuse large B-cell lymphoma is limited to non-germinal center B-cell-like subtype in late-elderly patients.
    Koh YW; Hwang HS; Park CS; Yoon DH; Suh C; Huh J
    Leuk Lymphoma; 2015; 56(9):2630-6. PubMed ID: 25573205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD30 expression and prognostic significance in R-EPOCH-treated patients with diffuse large B-cell lymphoma.
    Xu J; Oki Y; Saksena A; Desai P; Lin P; Tang G; Yin CC; You MJ; Thakral B; Medeiros LJ; Li S
    Hum Pathol; 2017 Feb; 60():160-166. PubMed ID: 27816715
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SIRPα-CD47 Immune Checkpoint Blockade in Anticancer Therapy.
    Veillette A; Chen J
    Trends Immunol; 2018 Mar; 39(3):173-184. PubMed ID: 29336991
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The interaction between signal regulatory protein alpha (SIRPα) and CD47: structure, function, and therapeutic target.
    Barclay AN; Van den Berg TK
    Annu Rev Immunol; 2014; 32():25-50. PubMed ID: 24215318
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel CD47: SIRPα dependent mechanism for the activation of STAT3 in antigen-presenting cell.
    Toledano N; Gur-Wahnon D; Ben-Yehuda A; Rachmilewitz J
    PLoS One; 2013; 8(9):e75595. PubMed ID: 24073274
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.